Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis
Status:
Completed
Trial end date:
2018-05-31
Target enrollment:
Participant gender:
Summary
This is a randomized-controlled clinical trial that will randomize 120 patients undergoing
clinically-indicated coronary artery bypass graft surgery to prasugrel at a dose of 10 mg
daily or matching placebo for 12 months, starting at the time of hospital dismissal from
surgery. The primary goal of the study is to determine whether prasugrel administration will
prevent thrombus (clot) formation within a saphenous vein graft at 12 months, as examined by
optical coherence tomography.